Prevention of type 1 diabetes: where we are and where we are going

被引：3

作者：

Frontino, Giulio ^{[1
]}

Guercio, Nuzio S. ^{[2
]}

Scaramuzza, Andrea ^{[3
]}

D'Annunzio, Giuseppe ^{[4
]}

Toni, Sonia ^{[5
]}

Citriniti, Felice ^{[6
]}

Bonfanti, Riccardo ^{[7
]}

机构：

[1] IRCCS San Raffaele Hosp, Diabet Res Inst, Dept Pediat, Milan, Italy

[2] ASL Salerno, Santa Maria Speranza Hosp, Div Pediat, Salerno, Italy

[3] ASST Cremona, Maggiore Hosp, Div Pediat, Cremona, Italy

[4] IRCCS Ist Giannina Gaslini, Unit Endocrinol, Clin Pediat, Genoa, Italy

[5] Meyer Children Hosp, Unit Diabetol & Endocrinol, Florence, Italy

[6] Pugliese Ciaccio Hosp, Dept Pediat, Catanzaro, Italy

[7] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Diabet Res Inst, Unit Pediat Diabet,Dept Pediat, Milan, Italy

来源：

MINERVA PEDIATRICS | 2021年 / 73卷 / 06期

关键词：

Diabetes Mellitus; type; 1; Prevention and control; Pediatrics; BETA-CELL FUNCTION; MESENCHYMAL STEM-CELLS; PRESERVES C-PEPTIDE; DOUBLE-BLIND; ISLET AUTOIMMUNITY; INCREASED RISK; DIETARY INTERVENTION; INFANT FORMULA; T-CELLS; INSULIN;

D O I：

10.23736/S2724-5276.21.06529-0

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550,000 children with T1D in the world; and about 86,000 children are diagnosed with T1D every year and its incidence is ever increasing. In this narrative review we will discuss current and future perspectives in T1D prevention strategies as well as their pitfalls. It is important to remember that for the first time one drug, in particular teplizumab (antibody anti-CD3) is going to be accepted for treatment in stage 2 of type 1 diabetes mellitus. This represent the onset of a new era.

引用

页码：486 / 503

页数：18

共 50 条

[1] Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, Xunrong
Herold, Kevan C.
Miller, Stephen D.
[J]. IMMUNITY, 2010, 32 (04) : 488 - 499
[2] HISTAMINE AND DIABETES: WHERE WE ARE AND WHERE ARE WE GOING
Rosa, A. C.
Pini, A.
Obara, I.
Sasse, A.
Sanchez-Jimenez, F.
Stark, H.
Masini, E.
Leurs, R.
Chazot, P. L.
[J]. INFLAMMATION RESEARCH, 2017, 66 : S42 - S42
[3] Diet and cancer prevention: Where we are, where we are going
Gonzalez, Carlos A.
Riboli, Elio
[J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2006, 56 (02): : 225 - 231
[4] Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Lord, Sandra
Greenbaum, Carla J.
[J]. PHARMACOLOGICAL RESEARCH, 2015, 98 : 3 - 8
[5] Screening and Prevention of Type 1 Diabetes: Where Are We?
Simmons, Kimber M.
Sims, Emily K.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (12): : 3067 - 3079
[6] Prevention of Ovarian Cancer: Where are We Now and Where are We Going?
Rodriguez, Isabel V.
Ghezelayagh, Talayeh
Pennington, Kathryn P.
Norquist, Barbara M.
[J]. CURRENT ONCOLOGY REPORTS, 2024,
[7] HIV prevention 2010: where are we now and where are we going?
Cohen, Myron S.
Fidler, Sarah
[J]. CURRENT OPINION IN HIV AND AIDS, 2010, 5 (04) : 265 - 268
[8] WHERE WE ARE, BUT WHERE ARE WE GOING
FELICIANO, DV
[J]. JOURNAL WATER POLLUTION CONTROL FEDERATION, 1982, 54 (09): : 1259 - 1266
[9] WHERE WE ARE, AND WHERE WE ARE GOING
SHULGIN, AT
[J]. JOURNAL OF THE FORENSIC SCIENCE SOCIETY, 1991, 31 (02): : 231 - 232
[10] WHERE WE ARE, AND WHERE WE ARE GOING
ELLARD, J
[J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1988, 22 (03): : 258 - 263

← 1 2 3 4 5 →